Form 4 for ABT Abbott Laboratories
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001620564-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-26 | 2026-02-24 | ABT | Salvadori Daniel Gesua Sive | EVP AND GROUP Pres | A - Grant | $0.00 | +21.6K | 153.9K | +16% | $0 |
| D | 2026-02-26 | 2026-02-24 | ABT | Salvadori Daniel Gesua Sive | EVP AND GROUP Pres | A - Grant | $0.00 | +89.2K | 89.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2026-02-24 | A | A | 21,644 | $0.00 | 153,877 | D | — | — | (F1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. |
| 2 | Derivative | Option (right to buy) | 2026-02-24 | A | A | 89,226 | $0.00 | 89,226 | D | $114.60 · 2027-02-24 to 2036-02-23 | 89,226 Common Shares | (F2) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,742 on February 24, 2027, 29,742 on February 24, 2028, and 29,742 on February 24, 2029. |